Asset Details
Do you wish to reserve the book?
Personalising PARP inhibitor combinations for metastatic castration-resistant prostate cancer
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
Personalising PARP inhibitor combinations for metastatic castration-resistant prostate cancer
Do you wish to request the book?
Personalising PARP inhibitor combinations for metastatic castration-resistant prostate cancer
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
Personalising PARP inhibitor combinations for metastatic castration-resistant prostate cancer
2025
Overview
The survival benefit in these two gene subgroups is consistent with the improvement in rPFS observed in an individual patient meta-analysis, 12 which included the TALAPRO-2 trial, investigating PARP inhibition in this disease setting. Because crossover to PARP inhibition was not performed as part of the trial for the placebo group, TALAPRO-2 did not directly test whether the longer and earlier exposure to talazoparib improves survival versus potentially shorter durations of treatment after progression. [...]PARP inhibitor plus ARPI combinations could be primarily administered at start of androgen deprivation therapy for metastatic castration-sensitive prostate cancer. 15 This setting has the additional advantage that tumour genomic sequencing is more likely to be successful. [...]TALAPRO-2 shows a clear benefit for enzalutamide plus talazoparib in patients with tumours that have DNA damage repair gene defects that sensitise to PARP inhibitors, by a process known as synthetic lethality.
